Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Mycophenolate mofetil (MMF) does not slow the progression of subclinical atherosclerosis in SLE over 2 years.

Kiani AN, Magder LS, Petri M.

Rheumatol Int. 2012 Sep;32(9):2701-5. doi: 10.1007/s00296-011-2048-y. Epub 2011 Jul 27.

2.

Vitamin D deficiency does not predict progression of coronary artery calcium, carotid intima-media thickness or high-sensitivity C-reactive protein in systemic lupus erythematosus.

Kiani AN, Fang H, Magder LS, Petri M.

Rheumatology (Oxford). 2013 Nov;52(11):2071-6. doi: 10.1093/rheumatology/ket271. Epub 2013 Aug 16.

3.

Predictors of progression in atherosclerosis over 2 years in systemic lupus erythematosus.

Kiani AN, Post WS, Magder LS, Petri M.

Rheumatology (Oxford). 2011 Nov;50(11):2071-9. doi: 10.1093/rheumatology/ker285. Epub 2011 Aug 28.

4.

Apolipoprotein-containing lipoprotein subclasses and subclinical atherosclerosis in systemic lupus erythematosus.

Kiani AN, Fang H, Akhter E, Quiroga C, Simpson N, Alaupovic P, Magder LS, Petri M.

Arthritis Care Res (Hoboken). 2015 Mar;67(3):442-6. doi: 10.1002/acr.22430.

5.

Progression of carotid intima-media thickness and plaque in women with systemic lupus erythematosus.

Thompson T, Sutton-Tyrrell K, Wildman RP, Kao A, Fitzgerald SG, Shook B, Tracy RP, Kuller LH, Brockwell S, Manzi S.

Arthritis Rheum. 2008 Mar;58(3):835-42. doi: 10.1002/art.23196.

6.

The effect of mycophenolate mofetil on disease development in the gld.apoE (-/-) mouse model of accelerated atherosclerosis and systemic lupus erythematosus.

Richez C, Richards RJ, Duffau P, Weitzner Z, Andry CD, Rifkin IR, Aprahamian T.

PLoS One. 2013;8(4):e61042. doi: 10.1371/journal.pone.0061042. Epub 2013 Apr 8.

7.

Tissue factor pathway inhibitor, vascular risk factors and subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis.

Mitchell CT, Kamineni A, Palmas W, Cushman M.

Atherosclerosis. 2009 Nov;207(1):277-83. doi: 10.1016/j.atherosclerosis.2009.04.024. Epub 2009 Apr 24.

8.

Systemic lupus erythematosus: the influence of disease-related and classical risk factors on intima media thickness and prevalence of atherosclerotic plaques--a preliminary report. Beneficial effect of immunosuppressive treatment on carotid intima media thickness.

Kisiel B, Kruszewski R, Juszkiewicz A, Raczkiewicz A, Bachta A, Kłos K, Duda K, Saracyn M, Szymański K, Młozniak-Cieśla A, Grabowska-Jodkowska A, Olesińska M, Bogusławska-Walecka R, Niemczyk S, Płoski R, Tłustochowicz W.

Acta Cardiol. 2015 Apr;70(2):169-75.

PMID:
26148377
9.

Reduced carotid intima-media thickness in systemic lupus erythematosus patients treated with cyclosporine A.

Oryoji K, Kiyohara C, Horiuchi T, Tsukamoto H, Niiro H, Shimoda T, Akashi K, Yanase T.

Mod Rheumatol. 2014 Jan;24(1):86-92. doi: 10.3109/14397595.2013.852838.

PMID:
24261763
11.

The efficacy of low-dose mycophenolate mofetil for treatment of lupus nephritis in Taiwanese patients with systemic lupus erythematosus.

Weng MY, Weng CT, Liu MF.

Clin Rheumatol. 2010 Jul;29(7):771-5. doi: 10.1007/s10067-010-1403-9. Epub 2010 Mar 2.

PMID:
20195879
12.

Carotid atherosclerotic alterations in systemic lupus erythematosus patients treated at a Brazilian university setting.

Telles RW, Lanna CC, Ferreira GA, Souza AJ, Navarro TP, Ribeiro AL.

Lupus. 2008 Feb;17(2):105-13. doi: 10.1177/0961203307085312.

PMID:
18250133
13.

Mycophenolate mofetil but not atorvastatin attenuates atherosclerosis in lupus-prone LDLr(-/-) mice.

van Leuven SI, Mendez-Fernandez YV, Wilhelm AJ, Wade NS, Gabriel CL, Kastelein JJ, Stroes ES, Tak PP, Major AS.

Ann Rheum Dis. 2012 Mar;71(3):408-14. doi: 10.1136/annrheumdis-2011-200071. Epub 2011 Sep 27.

14.

Carotid intima-media thickness among human immunodeficiency virus-infected patients without coronary calcium.

Hsue PY, Ordovas K, Lee T, Reddy G, Gotway M, Schnell A, Ho JE, Selby V, Madden E, Martin JN, Deeks SG, Ganz P, Waters DD.

Am J Cardiol. 2012 Mar 1;109(5):742-7. doi: 10.1016/j.amjcard.2011.10.036. Epub 2011 Dec 9.

15.

Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study.

Nannini C, Crowson CS, Matteson EL, Moder KG.

Lupus. 2009 Apr;18(5):394-9. doi: 10.1177/0961203308099242.

PMID:
19318390
16.

Cardiometabolic and immune factors associated with increased common carotid artery intima-media thickness and cardiovascular disease in patients with systemic lupus erythematosus.

Ammirati E, Bozzolo EP, Contri R, Baragetti A, Palini AG, Cianflone D, Banfi M, Uboldi P, Bottoni G, Scotti I, Pirillo A, Grigore L, Garlaschelli K, Monaco C, Catapano AL, Sabbadini MG, Manfredi AA, Norata GD.

Nutr Metab Cardiovasc Dis. 2014 Jul;24(7):751-9. doi: 10.1016/j.numecd.2014.01.006. Epub 2014 Feb 1.

PMID:
24787906
17.

Assessment of premature atherosclerosis in systemic lupus erythematosus patients with and without nephritis.

Sharma SK, Rathi M, Sahoo S, Prakash M, Dhir V, Singh S.

Lupus. 2016 Apr;25(5):525-31. doi: 10.1177/0961203315622822. Epub 2015 Dec 16.

PMID:
26678442
18.

Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus.

Mikołajczyk TP, Osmenda G, Batko B, Wilk G, Krezelok M, Skiba D, Sliwa T, Pryjma JR, Guzik TJ.

Lupus. 2016 Jan;25(1):18-27. doi: 10.1177/0961203315598014. Epub 2015 Aug 6.

PMID:
26251402
19.

A panel of biomarkers is associated with increased risk of the presence and progression of atherosclerosis in women with systemic lupus erythematosus.

McMahon M, Skaggs BJ, Grossman JM, Sahakian L, Fitzgerald J, Wong WK, Lourenco EV, Ragavendra N, Charles-Schoeman C, Gorn A, Karpouzas GA, Taylor MB, Watson KE, Weisman MH, Wallace DJ, Hahn BH.

Arthritis Rheumatol. 2014 Jan;66(1):130-9. doi: 10.1002/art.38204.

20.

The correlation between carotid artery atherosclerosis and clinical ischemic heart disease in lupus patients.

Eder L, Gladman DD, Ibañez D, Urowitz MB.

Lupus. 2014 Oct;23(11):1142-8. doi: 10.1177/0961203314537696. Epub 2014 May 29.

PMID:
24876099

Supplemental Content

Support Center